Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Apellis Pharmaceuticals ( (APLS) ) is now available.
On June 3, 2025, Apellis Pharmaceuticals held its Annual Meeting of Stockholders, where key decisions were made. A. Sinclair Dunlop, Alec Machiels, and Keli Walbert were elected as class II directors for a three-year term. Additionally, Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025. The stockholders approved the executive compensation and recommended holding future advisory votes on executive compensation annually.
The most recent analyst rating on (APLS) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Apellis Pharmaceuticals stock, see the APLS Stock Forecast page.
Spark’s Take on APLS Stock
According to Spark, TipRanks’ AI Analyst, APLS is a Neutral.
Apellis Pharmaceuticals’ stock score reflects strong revenue growth and strategic FDA milestones tempered by ongoing profitability challenges and negative market momentum. The stock’s valuation is affected by its negative earnings, and while corporate governance improvements are positive, they do not significantly alter the current financial outlook.
To see Spark’s full report on APLS stock, click here.
More about Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for autoimmune and inflammatory diseases.
Average Trading Volume: 2,587,552
Technical Sentiment Signal: Sell
Current Market Cap: $2.41B
See more insights into APLS stock on TipRanks’ Stock Analysis page.